ARRY - ARRAY BIOPHARMA INC
This page shows which of the focused investors we track hold ARRY and how their positions changed, so you can see how much conviction the group has in the stock.
In Q1 2018 it was held by 2 managers with an aggregate reported value of $12.41M, which is 0.00% of the combined portfolio.
As of Q1 2018, 2 tracked institutional managers held ARRY (ARRAY BIOPHARMA INC) with an aggregate reported value of $12.41M — 0.00% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades ARRY — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q1 2018
- Ticker
- ARRY
13F data is delayed and excludes shorts/non-13F assets.
Holders
| 1 | Leon Cooperman - Leon Cooperman | 0.12% | New | 200,000 | $3.26M |
Other instruments
Bonds, warrants, or other non-share-class principal positions in ARRY.
| 1 | Howard Marks - Oaktree Capital Management | Reduce -14.3% | 6,860,000 | $9.15M |
Loading holder history for ARRY…